A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases

BACKGROUND: Cabozantinib is an oral MET/VEGFR2 inhibitor. A recent phase II study of cabozantinib (100mg daily) demonstrated improved bone scans in subjects with metastatic castration-resistant prostate cancer (mCRPC), but adverse events (AEs) caused frequent dose reductions. This study was designed...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Lee, Richard J., Saylor, Philip J., Michaelson, M. Dror, Rothenberg, S. Michael, Smas, Malgorzata E., Miyamoto, David T., Gurski, Carol A., Xie, Wanling, Maheswaran, Shyamala, Haber, Daniel A., Goldin, Jonathan G., Smith, Matthew R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3684567/
https://ncbi.nlm.nih.gov/pubmed/23553848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0319
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller